VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES THE INITIATION OF
A CLINICAL STUDY EVALUATING ABSK043
IN COMBINATION WITH FURMONERTINIB MESYLATE TABLETS FOR
THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
02
2024-05
Next Day Disclosure Return
02
2024-05
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
30
2024-04
Next Day Disclosure Return
29
2024-04
Announcements and Notices
APPOINTMENT OF JOINT COMPANY SECRETARY AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND
8.17 OF THE LISTING RULES
26
2024-04
Next Day Disclosure Return
25
2024-04
Announcements and Notices
VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED ODD BY FDA
